Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04717388
Other study ID # APHP200761
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 15, 2021
Est. completion date April 15, 2026

Study information

Verified date February 2024
Source Assistance Publique - Hôpitaux de Paris
Contact Sophie DUPONT, MD, Ph.D
Phone 01 42 16 03 01
Email sophie.dupont@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

the investigators have recently shown that patients with drug-resistant temporal lobe epilepsy who have undergone brain surgery targeting the medial temporal lobe structures were more likely to develop tinnitus postoperatively. This discovery of a vulnerability to tinnitus associated with medial temporal lobe surgery to eliminate drug-refractory epileptic seizures provides a new clinical model of tinnitus, targeting temporal lobe regions as generators or mediators of this hearing disorder. The objective of this project is to study the impact of tinnitus on the cognitive, emotional, psychoacoustic and cerebral functioning associated with this hearing disorder, and to clarify the pathophysiology of tinnitus by comparing different groups of individuals with tinnitus (surgical epileptic patients or non-surgical ORL patients) to matched tinnitus-free groups (surgical tinnitus-free cases and healthy controls volunteer).


Description:

Tinnitus (known as "ringing in the ears") is a disabling medical condition. Its psychosocial impact is substantial, including anxiety, depression, stress, irritability, concentration and sleep disorder leading to detrimental effects on communication, education, professional fulfillment, mental health and quality of life. The cerebral bases of tinnitus and its consequence on human hearing health have received a lot of attention in the scientific literature. Yet, the relationship between the neurobiological dysfunction, psychological processes and clinical semiology of tinnitus remains poorly understood. Considering the current gaps in knowledge, there is a real need for clinical investigations into tinnitus-related brain changes and rigorous hearing, psycho-emotional, and cognitive assessments. the investigators recent discovery of a vulnerability to tinnitus associated with medial temporal lobe surgery (to treat refractory epilepsy) provides a new clinical model, which targets the temporal lobe regions as a tinnitus generator or mediator of its severity. The goal of this collaborative interdisciplinary study is to advance knowledge about the pathophysiology of tinnitus, as well as the socio-emotional, cognitive and psychoacoustic aspects associated to this hearing disorder. the investigators will first, characterize the subjective and self-reported hearing disorders with objective psychoacoustic, cognitive and affective measures in tinnitus sufferers and second, clarify the cerebral network underlying tinnitus and elucidate the role temporal lobe regions in the brain networks at play in surgical and non-surgical tinnitus. To this end, individuals with and without tinnitus, who had undergone or not a surgery will be compared in a 2 by 2 design. Investigating different patient cohorts with tinnitus who are well matched to both, healthy control populations and vulnerable clinical populations, without tinnitus is a valuable contribution of our proposal. Moreover, the psychological and hearing profiles of people with tinnitus will be examined in relation with their brain morphology and connectivity profiles.The project builds upon the internationally recognized leadership of the PI and her collaborators in the fields of auditory cognition and its neurobiological bases using neuropsychological, psychoacoustic, and neuroimaging methods in clinical populations. The members of the investigators consortium have all the necessary and unique expertise to carry out this innovative and interdisciplinary project.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date April 15, 2026
Est. primary completion date October 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Common Criteria for Inclusion : - Age = 18 years old - Good written and oral comprehension of the French language - Person affiliated to a Social Security scheme - Informed consent signed by the participant - Normal or corrected vision - Absence of known pre-existing neurological and/or degenerative disorders Group Specific Inclusion Criteria : Tinnitus+ Group - Suffering from subjective uni- or bilateral tinnitus, chronic (>3 months) and stable (no period of remission). Chir+ Group - Surgically treated for drug-resistant epilepsy of the temporal lobe (including the amygdala). Group Tinnitus- - Not suffering from tinnitus Group Chir- - Non epileptic - Not having undergone surgical treatment of the temporal lobe (including the tonsil) Exclusion criteria: - Presence of severe or profound deafness, uni or bilateral. - Under legal protection (guardianship, curators, etc.) Additional criteria for patients completing visit V2 : - MRI contraindicated or claustrophobic - Pregnant or breastfeeding woman.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
acoustics tests, Questionaries,
acoustics tests at V1 Questionaries at V1 cognitive emotional auditory
Radiation:
MRI
Anatomical and functional MRI at V2

Locations

Country Name City State
France Hôpital Européen Georges Pompidou Paris
France Service de Soins de Suite et Réadaptation (SSR) Neurologique, DMU de Neurosciences Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of the impact of tinnitus on executive cognitive functioning Measurement of executive control using a stroop test in people with and without chronic tinnitus. at the second visit, maximum 6 month after first visit.
Secondary Emotional functioning (anxiety and depression) Measures of Anxiety and Depression using: Hospital Anxiety and Depression Scale (HADS) : 14 rated items from 0 to 3. Seven questions are related to anxiety and seven to the depressive dimension, allowing for thus obtaining two scores (maximum score of each score = 21). at the second visit, maximum 6 month after first visit.
Secondary psycho-acoustic functioning Measurements of auditory functioning through hearing assessment (audiometry) :
- Self-assessment questionnaires for hearing loss: The self-assessment of hearing loss is based on a yes/no question: "Do you feel that you have a hearing loss or hearing loss?
at the second visit, maximum 6 month after first visit.
Secondary psycho-acoustic functioning Measurements of auditory functioning through hearing assessment (audiometry) :
- The noise hypersensitivity questionnaire( Khalfa, 2002) provides a score ranging from 0 (no hypersensitivity) to 42 (very strong hypersensitivity).
at the second visit, maximum 6 month after first visit.
Secondary psycho-acoustic functioning Measurements of auditory functioning through hearing assessment (audiometry) :
- The severity of tinnitus is measured by the Tinnitus Handicap Inventory (THI) questionnaire. Scores range from 0 (mild discomfort) to 100 (catastrophic impact).
at the second visit, maximum 6 month after first visit.
Secondary psycho-acoustic functioning Measurements of auditory functioning through hearing assessment (audiometry) :
- Hearing threshold measurement (pure tones from 125-16000Hz)
at the second visit, maximum 6 month after first visit.
Secondary psycho-acoustic functioning Measurements of auditory functioning through hearing assessment (audiometry) :
- Discomfort threshold measurement (with 1kHz sound)
at the second visit, maximum 6 month after first visit.
Secondary psycho-acoustic functioning Measurements of auditory functioning through hearing assessment (audiometry) : Evaluation of transient otoacoustic emissions (TEOAE) or by distortion product (DPOAE) at the second visit, maximum 6 month after first visit.
Secondary cognitive functioning, other than executive functioning (attention, memory) Measures of cognitive functioning :
- the Attentional Network Test (ANT) visual attention test.
ANT gives three attention scores based on reaction times. These scores represent the ability to direct attention, to be alert to surrounding stimuli and the executive part of attention.
at the second visit, maximum 6 month after first visit.
Secondary cognitive functioning, other than executive functioning (attention, memory) Measures of cognitive functioning :
- Mental Flexibility Score (Trail Making Test): The scores of the TMT (Trail Making Test) are expressed in time of completion. The faster the time to completion, the better the performance. So we have 2 scores, one for board A of the test: TMT-A and the other for board B of the test: TMT-B.
at the second visit, maximum 6 month after first visit.
Secondary cognitive functioning, other than executive functioning (attention, memory) Measures of cognitive functioning :
Measures of cognitive functioning :- Short-term memory score (auditive-verbal span). Score between 1 and 10, where 10 represents the best short-term memory score
at the second visit, maximum 6 month after first visit.
Secondary cognitive functioning, other than executive functioning (attention, memory) Measures of cognitive functioning :
Measures of cognitive functioning :- Working memory score (Brown-Peterson). The Brown Peterson gives a memorization score ranging from 0 to 100, where 100% is the best score.
at the second visit, maximum 6 month after first visit.
Secondary cognitive functioning, other than executive functioning (attention, memory) Measures of cognitive functioning :
- Episodic memory score in auditory modality. The episodic memory test in auditory mode gives a memorization score ranging from 0 to 100, where 100% represents a perfect memorization score.
at the second visit, maximum 6 month after first visit.
Secondary the reorganization of functional and structural brain connectivity maps Functional and structural brain connectivity measurements using brain imaging (fMRI, diffusion and resting MRI) :
- Volumetric measurement (in particular of the amygdala and the parahippocampal cortex)
at the third visit, maximum 18 month after the first visit
Secondary the reorganization of functional and structural brain connectivity maps Functional and structural brain connectivity measurements using brain imaging (fMRI, diffusion and resting MRI) :
- Measurement of anatomical connections between regions of interest (i.e. amygdala, auditory cortex, attention network including the precuneus and prefrontal cortex) from diffusion tensor imaging (TDI): fractional anisotropy (FA), mean diffusivity (MD), radial (RD) and axial (AD).
at the third visit, maximum 18 month after the first visit
Secondary the reorganization of functional and structural brain connectivity maps Functional and structural brain connectivity measurements using brain imaging (fMRI, diffusion and resting MRI) :
- Measurement of structural connectivity from fMRI at rest between predefined regions of interest and over new regions of interest defined during an attentional activation task
at the third visit, maximum 18 month after the first visit
Secondary the reorganization of functional and structural brain connectivity maps Functional and structural brain connectivity measurements using brain imaging (fMRI, diffusion and resting MRI) :
- Measurement of the amplitude of the synchrony of slow fluctuations and statistical dependencies in functional connectivity by comparing data from people with and without chronic tinnitus.
at the third visit, maximum 18 month after the first visit
Secondary Emotional functioning (stress) Measures of stress using Perceived Stress Scale (PSS-4): Lowest score: 0, Highest score: 16, Higher scores are correlated to more stress. at the second visit, maximum 6 month after first visit.
Secondary Emotional functioning (Auditory recognition of emotions) Measures of Auditory recognition of emotions using hearing tests with recordings at the second visit, maximum 6 month after first visit.
See also
  Status Clinical Trial Phase
Recruiting NCT05963542 - Efficacy of Online Acceptance and Commitment Therapy and Sound Therapy for Patients With Tinnitus and Insomnia N/A
Recruiting NCT04987502 - Virtual Reality and Subjective Tinnitus N/A
Recruiting NCT04404439 - Treatment of Tinnitus With Migraine Medications Phase 4
Recruiting NCT05533840 - Establishment and Application of a New Imaging System for Otology Based on Ultra-high Resolution CT
Completed NCT03552302 - Effects of Yoga Exercise on Participates With Tinnitus
Enrolling by invitation NCT02617953 - Objective Diagnosis Method and Efficacy of Repetitive Transcranial Magnetic Stimulation as a Treatment for Tinnitus N/A
Completed NCT02974543 - Somatosensory Stimulation to Alleviate Tinnitus N/A
Completed NCT02269839 - A Feasibility Study Assessing the Effectiveness of rTMS in Tinnitus N/A
Withdrawn NCT01663467 - Efficacy of Internet and Smartphone Application-delivered Tinnitus Retraining Therapy N/A
Completed NCT01929837 - Tinnitus rTMS 2013 N/A
Completed NCT01857661 - The Influence of the Sound Generator Combined With Conventional Amplification for Tinnitus Control: Blind Randomized Clinical Trial N/A
Completed NCT01927991 - Internet-based Self-help for Tinnitus: The Role of Support N/A
Terminated NCT01412918 - Inhibitor Masking Device & Sodium Channel, Voltage Gated, Type IX Alpha Subunit (SCN9) Gene Expression N/A
Completed NCT01480193 - New Therapy for Patients With Severe Tinnitus N/A
Completed NCT00748475 - Countering Stimulus-Induced Alpha-Desynchronization to Treat Tinnitus N/A
Completed NCT00371436 - Progressive Intervention Program for Tinnitus Management N/A
Completed NCT00733044 - Cost-effectiveness of Multidisciplinary Management of Tinnitus N/A
Active, not recruiting NCT05518682 - Assessment of Bimodal Stimulation Device Compliance and Satisfaction in Individuals With Tinnitus N/A
Recruiting NCT05212298 - Effects of Herbal Sleep Formula on Patients With Insomnia and Tinnitus N/A
Completed NCT06025097 - Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus. Early Phase 1